Services.
Overview
Independent medicinal chemistry and drug discovery consultant. Distinguished drug hunter with extensive medicinal chemistry, drug discovery and R&D expertise (Strategy, Pipeline Prioritization, Execution and Resourcing)
-
Small molecules, peptides and protein degraders in support of oncology, immunology, cardiometabolic, endocrine, fibrotic, pulmonary arterial hypertension (PAH), neuroscience and neurodegenerative diseases
-
All target classes, including PPIs, enzymes, kinases, receptors, allosteric and orthosteric inhibitors and activators, and other target families
Strategy
-
Portfolio: target choices-based tractability and probability of success (POS) to hit milestones keeping resources and timelines in mind (target Hit finding plan/research operating plan (ROP) Hit ID Lead Optimization Late Lead Optimization Candidate nomination Phase 1B/2A POC);
-
Choice of modality guided by project objectives, including target validation and/or delivery milestones, including small molecules, peptides, and protein degraders;
-
Medicinal chemistry and program strategies; and
-
Half-life extension strategies and drug delivery approaches, including absorption enhancers for oral peptides, PrEP formulations, and other methods
Operations
-
Due diligence on 3rd party assets while maintaining intellectual property firewall;
-
Property-based, multi-parameter, and structure guided drug design of hits and leads using singleton and parallel medicinal chemistry;
-
Optimization for potency, including binding and cellular assays, DMPK, in vivo pharmacology, developability, safety and toxicology, drug induced liver injury (DILI), translational PK/PD and biomarker plans;
-
Provision of expert guidance on portfolio and project execution to senior leaders, including CSOs or Heads of Drug Discovery; and
-
Participation in KOL forums for biotech and startup companies
